Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98 - Wikidata - wikimedia - TriplyDB

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

http://www.wikidata.org/entity/Q28290115

about

Follicular lymphoma: 2012 update on diagnosis and management Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas Follicular lymphoma: 2011 update on diagnosis and management Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma Follicular lymphoma: 2014 update on diagnosis and management Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years Role of Maintenance Rituximab (Rituxan) Therapy In the Treatment of Follicular Lymphoma Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.Rituximab in indolent lymphomas.The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.Rituximab maintenance in follicular lymphoma patients Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness.Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03 Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation.Management of indolent lymphoma: where are we now and where are we going.Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?Rituximab as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma: profile report.Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies.Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.Rituximab: current status as therapy for malignant and benign hematologic disorders.Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.Rituximab maintenance versus retreatment in follicular lymphoma.'Watch and wait' as initial management for patients with follicular lymphomas: still a viable strategy?Cost-effectiveness of rituximab in follicular lymphoma.ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).The role of monoclonal antibodies in the treatment of lymphomas.Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy.

P2860

Q22252956-1C9616AB-B132-4EE1-AF7C-EAFA38C56B30 Q26775837-8CC981D5-41E7-4DED-BA08-F0AD29F74E3D Q26784108-1D6BC084-B7F4-4278-908C-38B9EA96CFB2 Q26851450-3638BFE2-DA86-4D42-AAE4-EA012F7A9B43 Q27000310-148B4F4B-2D65-44B3-AA31-4588358060C3 Q27021850-101700AB-D4C5-4270-B986-9BF3451CC29E Q28073262-E73B4B62-A1A9-4FE1-8EEE-AC041B666632 Q28264598-70F0ACEE-E192-4A11-998C-D4DA0D0B5F94 Q28972464-681490C7-D64C-4C41-A602-EFFAC892151D Q30370665-71C65157-BF13-467B-814E-0A71F3EC2D0D Q33419840-60ECBCD6-7AE8-4EE1-B0FA-FCE2E92FE95A Q33621041-0C8FB8A6-30BD-445A-97F6-066849E301D9 Q33764062-C79023C5-A218-41A9-9AD2-6CE574C803D0 Q34470502-CB3C338C-3A47-4930-8957-E454A80007FD Q34646321-00675858-6707-4A24-B151-5F16B4373DBD Q35113379-7512ACD6-CEF9-4DC8-886D-DD0263A004F5 Q35205349-E8840355-490D-4537-9602-87B9F0801597 Q35700316-D5F67A30-82E9-43E7-903E-6B271B950FF0 Q35880154-EAD49A93-0673-4753-BE44-44E5C91239C0 Q36305803-4633A2D4-2479-4FEC-A559-A5C6FD9DDB67 Q36372975-B6D7ED5B-2F18-4BC5-8DA2-541541ACD219 Q36612574-97BEAF84-E116-4655-A0D2-E3C1B804C248 Q36784860-D550A5FE-5AEA-47C0-AF0A-10D6ED37094F Q36897238-2C760DE3-AEDA-4955-BEB5-029844D305BE Q36910325-F928F745-36DB-40FC-A7EB-8B6475A8385C Q37308467-E716DC99-B82A-41AE-B2E1-43E0D456F91E Q37875060-7C430849-9C48-433A-BC19-1D7A8E63629C Q37930456-100CC5AB-DA9D-40B1-ABC9-6A7340CAAD95 Q37937704-F23F896F-CBF3-48D1-9292-76840430E32B Q37940552-984ED163-EEC0-48F9-8129-D5833FFBD719 Q37948748-1ABF7BEB-1D8E-40E2-8CF9-7C2ED97B3561 Q37984551-A5D9B374-BA90-48B5-980B-A4F2CA12C273 Q38034939-4C169174-DDED-4F78-929D-B15406BF4220 Q38050339-3F8A8ED8-4F27-4A94-A074-B1E7B03841C8 Q38051428-00348515-7DAF-4780-AFAF-70E6D3DCBF8F Q38058840-11CAB709-D596-4555-B3AC-413364CA56A5 Q38061883-D080EDC7-5A80-4D33-A95F-39BD05BCA1EC Q38069595-A4FCE427-F4AD-4ED3-A39A-2B8636C43D51 Q38088002-261395CF-54A9-43E6-B25C-6D0BFC7FF08D Q38105625-9BCA91EE-0844-43EF-BC85-5EE784A57F92

P2860

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

http://www.wikidata.org/entity/Q28290115

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Long-term follow-up of patient ...... schedules in trial SAKK 35/98

@ast

Long-term follow-up of patient ...... schedules in trial SAKK 35/98

@en

Long-term follow-up of patient ...... schedules in trial SAKK 35/98

@nl

type

label

Long-term follow-up of patient ...... schedules in trial SAKK 35/98

@ast

Long-term follow-up of patient ...... schedules in trial SAKK 35/98

@en

Long-term follow-up of patient ...... schedules in trial SAKK 35/98

@nl

prefLabel

Long-term follow-up of patient ...... schedules in trial SAKK 35/98

@ast

Long-term follow-up of patient ...... schedules in trial SAKK 35/98

@en

Long-term follow-up of patient ...... schedules in trial SAKK 35/98

@nl

P1433

Q28290115-410C9AF0-F7EF-4C32-9DA5-1EE4507DCFE3

P1476

Q28290115-B8654011-2FCF-4335-B951-A9E002B16CA4

P2093

Q28290115-0DCB1E48-0BAE-4395-80EA-E60E76CA5FB2

Q28290115-25C13E23-7C54-4382-8C0C-24B465101D00

Q28290115-4DDBA8FE-5EAF-4D45-A3BA-010B3280619A

Q28290115-678F2FF9-3342-47F7-9B1D-D95E9F302D78

Q28290115-69611830-51E3-4404-86B6-AC62C3B057A1

Q28290115-74C97803-4E18-444D-A2C5-31C1BDCFBEFB

Q28290115-7D5E0F09-B835-4E56-AA7B-B1FFD3A83FE3

Q28290115-82549511-E66D-43B0-87C7-1DF31DCAB7DC

Q28290115-928B9AF7-B04A-44F0-AAF4-F6910AB8EE84

Q28290115-A60D6266-79D5-4E9B-96FE-47D0ED86A558

P304

Q28290115-6AA181CD-E44E-4A5F-9A50-27B93146C737

P31

Q28290115-77409224-44FA-4572-9AAE-2BA908BE1C47

P3181

Q28290115-8E9DE1DC-F999-4943-820D-7E13A78DEE78

P356

Q28290115-F4048673-4BB2-457C-A6EA-D007DEDBD3DF

P407

Q28290115-0871B913-7671-48FC-B75E-5F9DA2A98BEB

P433

Q28290115-707F27FE-D58B-4062-AA92-C29D96AA5E72

P478

Q28290115-4419F1A6-266D-4877-ABC6-C9F451A895AD

P50

Q28290115-2B7109EC-9461-4AC2-8576-94A087C656ED

P577

Q28290115-3D587245-4383-4037-BAED-B15349BC8A82

P698

Q28290115-B5F52841-D9A1-46EC-A1EC-4D5AEEA0654E

P3181

P356

JCO.2010.28.4786

P1433

Journal of Clinical Oncology

P1476

Long-term follow-up of patient ...... schedules in trial SAKK 35/98

@en

P2093

Andreas Lohri

http://www.w3.org/2001/XMLSchema#string

Daniel Vorobiof

http://www.w3.org/2001/XMLSchema#string

Emanuele Zucca

http://www.w3.org/2001/XMLSchema#string

Emmie Okkinga

http://www.w3.org/2001/XMLSchema#string

Marc Heizmann

http://www.w3.org/2001/XMLSchema#string

Michele Ghielmini

http://www.w3.org/2001/XMLSchema#string

Pierre-Yves Dietrich

http://www.w3.org/2001/XMLSchema#string

Roger Stupp

http://www.w3.org/2001/XMLSchema#string

Rolf Stahel

http://www.w3.org/2001/XMLSchema#string

Shu-Fang Hsu Schmitz

http://www.w3.org/2001/XMLSchema#string

P304

4480-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2532889

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2010.28.4786

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Martinelli

P577

2010-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20697092

http://www.w3.org/2001/XMLSchema#string